Suggested remit: To appraise the clinical and cost effectiveness of relugolix within its marketing authorisation for treating hormone-sensitive prostate cancer.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
6187
|
Provisional Schedule
| Committee meeting |
13 June 2024 |
Project Team
Email enquiries
| External Assessment Group |
Southampton Health Technology Assessment Centre (SHTAC), University of Southampton |
Stakeholders
| Companies sponsors |
Accord Healthcare Limited |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Prostate Cancer UK |
| |
Tackle Prostate Cancer |
| Professional groups |
Association of Cancer Physicians |
| |
British Association of Urological Surgeons |
| |
British Uro-Oncology Group |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Associated public health groups |
Public Health Wales |
| |
UK Health Security Agency |
| Comparator companies |
AstraZeneca (goserelin) (confidentiality agreement not signed, not participating) |
| |
Ferring Pharmaceuticals (degarelix, triptorelin) (confidentiality agreement not signed, not participating) |
| |
Ipsen (triptorelin) (confidentiality agreement signed, participating) |
| |
Neon Healthcare (buserelin) (confidentiality agreement not signed, not participating) |
| |
Takeda (leuprorelin) (confidentiality agreement not signed, not participating) |
| |
Typharm (leuprorelin) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
01 November 2023
|
Invitation to participate |
|
30 August 2023 - 27 September 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6187 |
|
23 December 2022
|
In progress. DHSC referral received |
|
12 September 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual